Rockwell Medical, Inc. $RMTI
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Wixom, MI
- Fiscal year end
- December 31
- Shares outstanding
- 4,030,465 [10-Q 2026-08-13]
What the company doesAI summary of filing
Rockwell Medical develops, manufactures, and distributes hemodialysis concentrates and related products for dialysis providers in the United States and internationally. The company is a revenue-generating supplier of liquid and dry acid concentrates and bicarbonate concentrates used in dialysis treatment, which it manufactures at facilities in Michigan, Texas, and Iowa and delivers primarily through its own fleet and third-party carriers. Rockwell serves 294 customers, including all five leading U.S. dialysis providers, with dialysate concentrates representing 100% of 2025 revenue. The company generated approximately 88% of sales from U.S. customers and 12% from international sales in 2025. [10-K 2026-03-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $35.12M | −$2.78M | $1.91M | $10.52M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $69.26M | −$5.31M | −$659.0K | $10.71M | [10-K 2026-03-26] |
| FY ended Dec 2024 | $101.49M | −$480.0K | $4.20M | $15.66M | [10-K 2026-03-26] |
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-08 | 32,318,806 | [10-Q 2024-11-12] |
| 2025-03-14 | 34,056,920 | [10-K 2025-03-20] |
| 2025-05-06 | 34,174,687 | [10-Q 2025-05-12] |
| 2025-08-06 | 34,430,352 | [10-Q 2025-08-14] |
| 2025-11-07 | 39,405,302 | [10-Q 2025-11-12] |
| 2026-03-23 | 39,405,302 | [10-K 2026-03-26] |
| 2026-04-30 | 39,470,299 | [10-Q 2026-05-07] |
| 2026-08-10 | 4,030,465 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2024-10-08; declared effective 2024-10-21 [S-3 2024-10-08]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-05-08. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-05-08 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-05-08] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-01 | Strobeck Mark | sell | 1,000 | $8.42 | [4 2026-10-05] |
| 2026-07-01 | Dawson Joseph H | grant | 9,633 | — | [4 2026-07-06] |
| 2026-07-01 | Nissenson Allen | grant | 9,633 | — | [4 2026-07-06] |
| 2026-07-01 | Lau Joan | grant | 9,633 | — | [4 2026-07-06] |
| 2026-07-01 | Radie Robert S | grant | 9,633 | — | [4 2026-07-06] |
| 2026-07-01 | Cooper John G | grant | 9,633 | — | [4 2026-07-06] |
| 2026-07-01 | Chole Timothy | grant | 15,000 | — | [4 2026-07-06] |
| 2026-07-01 | Hunter Heather | grant | 15,000 | — | [4 2026-07-06] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-13 | 8-K | Regulation FD disclosure |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations |
| 2026-07-20 | 8-K | Other events |
| 2026-06-29 | 8-K | Change to security holder rights; Charter, bylaws or fiscal year change |
| 2026-06-15 | 8-K | Shareholder vote results |
| 2026-05-08 | 8-K | Listing notice or transfer |
| 2026-05-07 | 8-K | Regulation FD disclosure |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Results of operations |
| 2026-04-30 | DEF 14A | Proxy statement |
| 2026-04-20 | PRE 14A | Proxy statement |
Alerts for $RMTI
Email me when Rockwell Medical, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.